Inactive Instrument

Eleven Biotherapeutics Inc Stock price Nasdaq

Equities

US2862211065

Sales 2023 * 13.53M Sales 2024 * 7.83M Capitalization 91.61M
Net income 2023 * -88M Net income 2024 * -102M EV / Sales 2023 * 6.77 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 11.7 x
P/E ratio 2023 *
-0.9 x
P/E ratio 2024 *
-1.06 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Inflation Data -2- DJ
Carisma Therapeutics' First Lead Candidate Under Moderna Deal to Target Cancer Treatment MT
Carisma Therapeutics Obtains FDA Clearance to Study Potential Solid Tumor Therapy MT
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stocks Look to -2- DJ
Carisma Therapeutics Inc. Presents Pre-Clinical Proof of Concept for in vivo CAR-M Using mRNA Platform in Collaboration with Moderna at SITC CI
Carisma Therapeutics Inc. to Present First Results from in Vivo Car-M Collaboration with Moderna at SITC 2023 CI
Capital Starts Carisma Therapeutics at Overweight With $10 Price Target MT
Carisma Therapeutics, Inc. Announces Latest Data from Phase 1 Clinical Trial of CT-0508 At 8th Annual CAR-TCR Summit CI
HC Wainwright Adjusts Price Target on CARISMA Therapeutics to $11 From $10, Keeps Buy Rating MT
North American Morning Briefing : Investors Await -2- DJ
Evercore ISI Initiates CARISMA Therapeutics at Outperform With $12 Price Target MT
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with Keytruda(R) (Pembrolizumab) in Patients with Her2 Overexpressing Solid Tumors CI
More news
Sesen Bio, Inc. is a late-stage clinical company engaged in advancing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company's advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
Sector
-
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Carisma Therapeutics, Inc.
  4. Stock Eleven Biotherapeutics Inc - Nasdaq